Format

Send to

Choose Destination
See comment in PubMed Commons below
Hum Vaccin Immunother. 2012 Sep;8(9):1179-91. doi: 10.4161/hv.20738. Epub 2012 Aug 21.

Immunotherapy in ovarian cancer.

Author information

1
Division of Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

Abstract

Ovarian cancer is the most deadly gynecologic malignancy, with more than 15,000 deaths anticipated in 2012. While approximately 80% of patients will respond to frontline chemotherapy, more than 60% of patients will experience disease recurrence and only 44% will be alive at 5 y. Host anti-tumor immune responses are associated with a significant improvement in overall survival for women with ovarian cancer. By bolstering these responses, it may therefore be possible to significantly influence the prognosis of women with this lethal disease. In this review, we will focus on innovative immune-based strategies which are currently being investigated in the treatment of ovarian cancer.

PMID:
22906947
PMCID:
PMC3579897
DOI:
10.4161/hv.20738
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center